The potential US$400b merger talks between AstraZeneca and Bristol Myers Squibb have thrown a fresh spotlight on the ecosystem that sits behind every big pharma deal. Advisory, legal, and M&A service providers that focus on healthcare can feel the ripple effects of this kind of headline, even while AstraZeneca shares themselves react sharply, with a drop of over 7% on the news. This article looks at how this development might influence deal related activity and what that could mean for investors. It will walk through 3 stocks from the screener that appear positively exposed to this news driven theme.

Huron Consulting Group (HURN)

Overview: Huron Consulting Group is a Chicago based professional services company that helps hospitals, universities, and commercial clients improve financial performance, operations, and digital systems, including areas like enterprise software, AI, and data management. It also provides research administration tools, revenue cycle outsourcing, and regulatory and risk consulting across healthcare, education, and a range of commercial industries.

Operations: Huron generates approximately US$0.9b in revenue from Healthcare, US$515m from Education, and US$360m from Commercial clients, with all reported revenue of about US$1.8b coming from the United States.

Market Cap: US$2.6b

Huron Consulting Group sits at the intersection of healthcare, education, and commercial clients that are under pressure to improve margins and deal with growing regulatory and digital complexity. This can make its services especially relevant when large pharma deals such as AstraZeneca and Bristol Myers Squibb are on the table. The company is seeing strong demand for AI enabled and performance improvement projects and recently lifted 2026 revenue and EPS guidance, while also buying back shares and pursuing tuck in acquisitions. At the same time, high debt, reliance on healthcare and education budgets, and an already busy acquisition program leave little room for missteps. That mix of opportunity and execution risk is what makes Huron worth a closer look in this M&A driven theme.

Huron’s accelerating push into AI enabled performance projects and healthcare M&A advice is only half the story. See how the 5 key rewards and 2 important warning signs might reshape your view of its debt load and acquisition spree.

Gateley (Holdings) (AIM:GTLY)

Overview: Gateley (Holdings) is a UK based legal and consultancy group that advises companies on corporate deals, disputes, employment, pensions, tax, property and construction, often providing bundled legal and consulting services across complex projects and transactions.

Operations: Gateley (Holdings) generates about £100.6m in revenue from Property, £40.4m from Corporate, £34.8m from Business Services and £18.5m from People, with most revenue coming from the United Kingdom and smaller contributions from Europe, Asia, the Middle East and the Americas.

Market Cap: £79.9m

Gateley (Holdings) sits in a useful spot for investors watching the AstraZeneca and Bristol Myers Squibb talks, because it already supports M&A, disputes and restructuring work for corporates, including in healthcare and pharma. Revenue is guided at about £193m for FY26 with earnings forecast to grow, yet the stock trades below some analysts’ valuation estimates and the Simply Wall St DCF fair value. At the same time, debt coverage by cash flow is weak, dividend payouts are being reset after a cut and CEO succession adds another layer of uncertainty. That mix of discounted pricing, demand for complex advisory work and financial and governance questions is why Gateley could be of interest within this deal heavy theme.

Gateley (Holdings) looks like a reset story hiding in plain sight, with guided FY26 revenue and earnings forecasts not fully reflected in the current share price. Get the full picture in the analyst forecasts for Gateley (Holdings) that also flags what could change the story next.

Moelis (MC)

Overview: Moelis & Company is a global investment bank that advises clients on mergers and acquisitions, restructurings, capital raises, and other corporate finance decisions for large public companies, private businesses, financial sponsors, and government related entities.

Market Cap: US$5.6b

Moelis sits in a sweet spot for investors watching the potential AstraZeneca and Bristol Myers Squibb mega deal, because it focuses on complex advisory work and already has a strong presence in large scale M&A and private capital transactions. Recent quarters show record revenue, an advisory pipeline reported at more than 80% above the prior year, and high returns on equity. The stock still trades below the Simply Wall St DCF estimate and around analyst price targets. The flip side is meaningful earnings volatility, an unstable dividend record, and high compensation and funding risk that can bite if deal activity slows. That mix of strong fundamentals, a busy deal backdrop and very real risk factors makes Moelis a stock worth closer attention within this pharma M&A theme.

Moelis has record revenue and an advisory pipeline reported at more than 80% above the prior year, yet the real story sits in how that flows through profits and risk. The analysis report for Moelis hints at one detail that could change how you see this deal heavy pipeline

The three companies in this article are just a starting point, since the full Pharmaceutical Deal Advisors and M&A Service Providers screener surfaced 31 more stocks with narratives tied to pharma deal flow, specialist advisory revenue, and balance sheet strength. Use Simply Wall St to identify and analyze the specific catalysts, risk profiles, and M&A exposure that fit your own highest conviction ideas in this theme.

Take Control of Your Investment Journey

If Gateley (Holdings) or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Pharma Deals

Fresh ideas move first. By the time a breakout theme hits headlines, the early entry window can be dropping fast. Scan these under the radar lists while it matters and act now.

• Spot income workhorses built for staying power by scanning the 9 dividend fortresses before yields get squeezed and the crowd chases the same familiar tickers.
• Hunt for early AI compounding stories across the 70 profitable AI stocks that aren't just burning cash while they are still under the radar for now and before momentum traders pile in.
• Track the backbone of future infrastructure with the 35 power grid technology and infrastructure stocks before capital floods in and pushes the strongest operators out of easy reach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.